9vHPV vaccine (Papillomavirus Infections Vaccine)

Category Resource

Explore licensed vaccines, adverse event reporting data, and history for this disease.

View Papillomavirus Infections Vaccine Guide →

Development Phase Phase 3 Clinical Trial Primary Status

Platform Technology Biological (unspecified platform) Biologic Architecture

Target Indication Papillomavirus Infections Pathogen / Antigen

Last Verified 2026-07-10 Tier 1 Multi-Source Checked

Multi-Jurisdiction Regulatory Status

Official licensing, rolling submissions, or authorization status tracked across major health authorities.

Regulatory Authority	Status & Details
US FDA	Not Filed / Pre-submission
EMA (Europe)	Not Filed / Pre-submission
Health Canada	Not Filed / Pre-submission
TGA (Australia)	Not Filed / Pre-submission

Scientific Profile & Documentation

Platform Architecture: Biological (unspecified platform)
Lead Developer: Merck Sharp & Dohme LLC
Next Expected Milestone: Primary completion (most advanced trial): 2029-08-03 (registry estimate)
Analyst & Development Notes: Auto-grouped from 5 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.
Primary Source Documentation: ClinicalTrials.gov NCT05450705 →
Additional Sources & Literature: NCT05314023 on ClinicalTrials.gov (2026-07-10)
NCT05285826 on ClinicalTrials.gov (2026-07-10)
NCT04199689 on ClinicalTrials.gov (2026-07-10)
NCT04708041 on ClinicalTrials.gov (2026-07-10)

Registered Clinical Trials & Studies

Direct registry links to active, completed, or pivotal registration studies across phases.

NCT05450705 Phase 3 Clinical Trial

V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071)

Status: Active / Ongoing • Expected Readout: 2029-08-03

NCT05314023 Phase 3 Clinical Trial

Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)

Status: Active / Ongoing • Expected Readout: 2029-02-19

NCT05285826 Phase 3 Clinical Trial

Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)

Status: Active / Ongoing • Expected Readout: 2029-05-25

NCT04199689 Phase 3 Clinical Trial

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHP

Status: Active / Ongoing • Expected Readout: 2027-08-27

NCT04708041 Phase 3 Clinical Trial

Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)

Status: Active / Ongoing • Expected Readout: 2029-10-23

Milestone Overview

Stage Verification

Phase 3 Clinical Trial confirmed as of 2026-07-10.
Target Milestone

Primary completion (most advanced trial): 2029-08-03 (registry estimate)

Vaccine Data Navigator Candidate Profile Registry:

This candidate profile is indexed across all clinical development levels (Preclinical through Phase 1–3, Regulatory Filing, and Licensure) from primary registry databases (ClinicalTrials.gov, WHO ICTRP, FDA CBER, EMA, Health Canada, TGA Australia). Data are updated continuously to track global biologic and vaccine pipelines.